Sabizabulin inhibited the cell release and cell-to-cell spread of poxvirus in a preclinical study
Veru further expands study of sabizabulin for the treatment of poxvirus acute respiratory distress syndrome
Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with